This article was downloaded by: On: 24 January 2011 Access details: Access Details: Free Access Publisher Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



LIQUID

## Journal of Liquid Chromatography & Related Technologies

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597273

## A NEW HIGH PERFORMANCE THIN-LAYER CHROMATOGRAPHY (HPTLC) METHOD FOR DETERMINATION OF THEOPHYLLINE IN PLASMA

A. Jamshidi<sup>a</sup>; M. Adjvadi<sup>a</sup>; S. Shahmiri<sup>b</sup>; A. Masoumi<sup>b</sup>; S. W. Husain<sup>c</sup>; M. Mahmoodian<sup>a</sup> <sup>a</sup> Darou-Pakhsh Pharmaceutical Research Center, Tehran, Iran <sup>b</sup> Department of Chemistry, Science & Research Branch, Islamic Azad University, Tehran, Iran <sup>c</sup> Department of Chemistry, University of Tarbiat Moalem, Tehran, Iran

Online publication date: 13 January 2005

**To cite this Article** Jamshidi, A., Adjvadi, M., Shahmiri, S., Masoumi, A., Husain, S. W. and Mahmoodian, M.(1999) 'A NEW HIGH PERFORMANCE THIN-LAYER CHROMATOGRAPHY (HPTLC) METHOD FOR DETERMINATION OF THEOPHYLLINE IN PLASMA', Journal of Liquid Chromatography & Related Technologies, 22: 10, 1579 – 1587 **To link to this Article: DOI:** 10.1081/JLC-100101753

**URL:** http://dx.doi.org/10.1081/JLC-100101753

## PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

# A NEW HIGH PERFORMANCE THIN-LAYER CHROMATOGRAPHY (HPTLC) METHOD FOR DETERMINATION OF THEOPHYLLINE IN PLASMA

A. Jamshidi,<sup>1</sup> M. Adjvadi,<sup>1</sup> S. Shahmiri,<sup>2</sup> A. Masoumi,<sup>2</sup> S. W. Husain,<sup>3</sup> M. Mahmoodian<sup>1</sup>

<sup>1</sup> Darou-Pakhsh Pharmaceutical Research Center P. O. Box 13185/877 Tehran, Iran

> <sup>2</sup> Department of Chemistry Science & Research Branch Islamic Azad University P. O. Box 19395/1775 Tehran, Iran

<sup>3</sup> Department of Chemistry University of Tarbiat Moalem 49 Dr. Mofateh Ave. 15614 Tehran, Iran

## ABSTRACT

A new high-performance thin-layer chromatography (HPTLC) method for the determination of theophylline in plasma has been developed. Plasma samples were prepared by the internal reference method. Denaturation was carried out through cold centrifugation.

1579

Copyright © 1999 by Marcel Dekker, Inc.

www.dekker.com

Separation of the drug from the complex matrix was accomplished within a short 50 mm migration distance and 25 min migration time on silica gel 60 F 254 layers using tolueneisopropanol-acetic acid (80:20:5) as the mobile phase. The analyte was quantified by absorbance/reflectance densitometry using peak-area ratio analysis. Validation parameters were investigated considering the special features of the method.

## **INTRODUCTION**

Theophylline, 1,3-dimethylxanthine, was introduced into medical use several decades ago for its bronchodilator properties. The therapeutic range of theophylline in plasma is, consequently, narrow and the management of the drug in clinical practice is complicated by several factors which influence the disposition of theophylline, e.g., age, smoking habits, diet, disease, obesity, and drugs all contribute to the wide inter-individual variability of theophylline clearance. As a consequence, the monitoring of plasma concentration in patients on theophylline treatment is now current practice.<sup>1</sup>

High performance liquid chromatography (HPLC) has been used as the suitable method for the determination of theophylline.<sup>2-8</sup> Since HPTLC is a powerful tool for the screening of drugs and other substances,<sup>9,10</sup> it may be regarded as a renaissance of this practical and effective method. Therefore, we have developed a more selective, sensitive, and cost effective HPTLC method for determination of theophylline in human plasma. Our method permits assay of at least 17 samples, using a three-point, in-system calibration on a single  $10\times20$  cm pre-coated plate.

#### **EXPERIMENTAL**

Theophylline, caffeine, and acetaminophen (Sigma, St. Louis, USA); toluene, isopropanol, acetic acid, and chloroform (Merck, Darmstadt, Germany); ethyl acetate (Fluka AG, Bush, Switzerland); methanol (Riedel-de-Haen, Germany); plasma samples (Amiralmomenin Hospital, Tehran, Iran).

#### Method

## **Standard solutions**

Stock solutions of theophylline and acetaminophen (1mg/mL) were prepared by dissolving accurately weighed amounts of the substances in

#### THEOPHYLLINE IN PLASMA

methanol using 10 mL, acid-washed, volumetric flasks. Required concentrations were made through appropriate dilutions. Internal reference standard acetaminophen stock solution was added to each diluted solution. These solutions were used for calibration graph construction.

## **Sample solutions**

Samples were prepared using 2 mL of plasma in 10 mL, acid-washed, test tubes. They were spiked to contain different amounts of theophylline and 100  $\mu$ L of the internal reference standard of acetaminophen (1 mg/mL stock solution) was added. Plasma samples were deproteinized with 0.2 mL of 1 M hydrochloric acid and centrifuged at 3000 rpm and 5°C for 15 min. The supernatant was extracted with 5 mL mixture of chloroform-isopropanol (1:1). The organic phase was transferred to another acid-washed test tube and evaporated at 40°C (water bath) under a stream of nitrogen. The dry residue was dissolved in 120  $\mu$ L of methanol. This methanolic solution was used for the HPTLC procedure.

## Thin layer chromatography

HPTLC was performed on  $10\times20$  cm silica gel 60 F 254 pre-coated plates (Art. 5642, Merck). The plates were previously developed in chloroformmethanol (1:1) and stored in a 60 °C oven for 15 min to remove elutable components and produce a clean layer background for visual evaluation, and a straighter baseline and high signal-to-noise ratio when scanning.<sup>11</sup> Ascending chromatography was performed in a twin-trough TLC chamber (Camag, Muttenz, Switzerland), using toluene-isopropanol-acetic acid (80:10:5) as the mobile phase, without chamber saturation. The migration distance was 50 mm and migration time about 25 min. Bands of samples and standards (4mm) were applied with a Camag Linomat IV using the data-pair technique.<sup>12</sup> The chromatoplates were dried by nitrogen flow. The spots were detected under UV light at 254 nm. Scanning was performed at 278 nm with a Camag TLC Scanner II in the reflectance/absorbance mode.

## **RESULTS AND DISCUSSION**

#### Selectivity

Baseline separation was obtained between theophylline, caffeine (as the most probable interfering compound in human plasma), and acetaminophen, which is used as internal standard (Fig. 1). This baseline separation was also obtained between theophylline, acetaminophen, and matrix components (Fig. 2).




Figure 1. Baseline separation between caffeine, 1, theophylline, 2, and acetaminophen, 3.

## Table 1

## **Calibration Data**

Concentration (ng/spot)	Peak Area Ratio (x 1000)		
80.2	708.7		
90.2	745.5		
100.2	778.8		
110.2	880.1		
120.2	919.2		
130.3	999.9		
140.3	1086.1		
150.3	1062.4		
160.3	1114.2		




Figure 2. Baseline separation between theophylline, 2, acetaminophen, 3, and other matrix components.




Figure 3. Calibration function for theophylline in the linear working range.




Figure 4. Residual plot.

#### **Calibration and Working Range**

In quantitative TLC, the results are highly influenced by the quality of the calibration.<sup>13</sup> Lack of linearity can easily be overcome by specifying working ranges with linear response.<sup>14</sup> The linearity of peak area ratio to different concentrations of theophylline was determined over a concentration range of 80 to 160 ng/spot (Table 1, Fig. 3). Residuals were plotted as an illustrative tool to check the adequacy of the regression model.<sup>15,16</sup> The residuals were distributed at random around the regression zero line (Fig. 4) and the calibration graph can be assumed to be linear.

## Accuracy

Accuracy of the method gives information about the recovery of the drug from the sample, and about matrix effects.<sup>16</sup> It was tested by determination of efficiency of recovery of analyte used for spiking. Three laboratory-made

## Table 2

## **Accuracy of Theophylline Determination**

Expected (ng/spot):	85.0	85.0	120.3	120.3	155.8	155.8
Found (ng/spot):*	84.1	85.3	118.9	121.6	156.2	156.2
Recovery (%):	98.9	100.3	98.8	101.1	100.2	100.2

\* Average of four different experiments.

## Table 3

## **Repeatability Data**

Measurement	Theophylline Concentration (ng/spot)*				
	Ι	II	III		
1	833.3	118.9	156.2		
2	83.3	118.9	156.2		
3	84.1	118.8	156.0		
4	84.4	118.9	156.0		
5	83.2	118.8	156.3		
6	83.3	118.8	156.2		
7	84.4	118.8	156.2		
Mean (ng/spot)	83.7	118.8	156.1		
SD	0.56	0.05	0.11		
RSD	0.69	0.04	0.07		

\* I: Lower region of the calibration graph; II: Middle region of the calibration graph; III: Upper region of the calibration graph.

samples were prepared in duplicate, spiked with theophylline in different amounts covering the lower, middle, and upper region of the calibration graph. The analyte concentration were determined in duplicate, using in-system calibration. The results are shown in Table 2.

## Repeatability

Repeatability of the method was determined by multiple analysis using the same method of measurement, analyst, instruments, and location over a short

period of time.<sup>14,17,18</sup> Three laboratory-made samples in the lower, middle, and upper region of the calibration graph were examined. The results are shown in Table 3.

## CONCLUSION

An accurate and precise HPTLC method for determination of theophylline in human plasma has been developed. The analyte is well separated from matrix components and assayed for theophylline. High sample throughput and ease of operation are significant advantages of the method.

#### ACKNOWLEDGMENT

The authors thank Islamic Azad University for some laboratory facilities.

#### REFERENCES

- 1. V. Rovei, F. Chanoine, M. Strolinbenedetti, Brit. J. Clin. Pharm., **14**, 769-778 (1982).
- 2. T. Sakata, A. Matsuura, T. Kitagawa, Chromatographia, **33**(7/8), 339-343 (1992).
- J. Hempenius, J. Wieling, J. H. G. Jonkaman, O. E. deNoord, P. M. J. Coengracht, D. A. Doornbos, J. Pharm. Biomed. Anal., 8(4), 313-320 (1990).
- M. J. Cooper, B. L. Mirkin, M. W. Anders, J. Chromatogr., 143, 324-326 (1977).
- J. Blanchard, S. Harvey, W. J. Morgan, J. Chromatogr. Sci., 28, 303-306 (1990).
- 6. M. C. Gennaro, C. Abrigo, P. Biglino, Analyst, 117, 1071-1074 (1992).
- 7. N. Daoud, T. Arvidson, K. G. Wahlund, J. Pharm. Biomed. Anal., **4**(**2**), 253-260 (1986).
- B. K. Shablin, D. M. Kalamandis, I. L. Smith, Anal. Lett., 24(2), 199-207 (1991).

- 9. P. D. Sethi, **High Performance Thin Layer Chromatography**, CBS Publishers, New Delhi, 1995.
- B. Renger, H. Jehle, M. Fischer, W. Funk, J. Planar Chromatigr.-Mod. TLC, 8, 269-278 (1995).
- 11. H. Deinstrop, J. Planar Chromatogr.- Mod. TLC, 6, 313-318 (1993).
- 12. H. Bethke, W. Santi, R. W. Frei, J. Chromatogr. Sci., 12, 392-396 (1974).
- 13. B. Renger, J. A. O. A. C. Int., 76, 7-13 (1993).
- 14. International Vocabulary of Basic and General Terms in Metrology, (BIPM, IEC, IFCC, ISO, IUPAC, OIML); ISO Central Secretariat, 1, rue de Varambe, CH-1211 Geneva 20, Switzerland.
- "CPMP Working Party on Quality of Medicinal Products: Tripartite ICH Text: Validation of Analytical Procedures," Draft No. 3 (III/5626), Brussels, September 1993.
- K. F. Fodor, A. N. Tura¢k, Z. Ve¢gh, J. Planar Chromatogr.-Mod. TLC, 8, 349-365 (1995).
- 17. The Rules Governing Medicinal Products for Human Use in the European Community, Volume III, Add. Jul., Brussels, 1990 (CB-59-90-936-EN-C).
- Note for Guidance: Validation of Analytical Procedures, Finland, Committee for Proprietary Medicinal Products, Document No. III/5626/94-EN, Brussels, 1994.

Received May 28, 1998 Accepted July 30, 1998 Manuscript 4903-TLC

# **Request Permission or Order Reprints Instantly!**

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the <u>U.S. Copyright Office</u> for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on <u>Fair Use in the Classroom</u>.

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our <u>Website</u> <u>User Agreement</u> for more details.

# **Order now!**

Reprints of this article can also be ordered at http://www.dekker.com/servlet/product/DOI/101081JLC100101753